Myocyte enhancer factor 2 transcription factor (MEF2)

Myocyte enhancer factor 2 (MEF2) refers to a family of transcription factors (MEF2A, MEF2B, MEF2C, MEF2D) that regulate gene expression critical for the differentiation, development, and maintenance of muscle, heart, neuronal, and other cell types[1][2][3][4][5]. MEF2 proteins contain a highly conserved N-terminal MADS-box DNA binding domain and an adjacent MEF2 domain, which facilitate DNA binding and dimerization, while the divergent C-terminal transactivation domain mediates transcriptional activity and co-factor recruitment[1][3][4]. MEF2 factors are central in muscle gene expression, cardiovascular development, neuronal differentiation, and cellular stress responses. Dysregulation of MEF2 family members is associated with cancer, cardiovascular disorders, and neurodevelopmental diseases. Although MEF2 itself is not directly targeted by approved drugs, its regulatory pathways—particularly HDAC-mediated repression—form the basis for ongoing therapeutic strategies. Due to fundamental roles in multicellular development, therapeutic targeting of MEF2 presents notable specificity and toxicity challenges[1][2][3][4][5].

Other names

MEF2 transcription factor familyMef2Myocyte enhancer factor 2MEF2AMEF2BMEF2CMEF2D

HDAC inhibition increases MEF2 activity by preventing deacetylation, promoting transcriptional activation[1][4]. Disruption of MEF2–DNA binding or dimerization inhibits its function. Modulation of co-factor interactions (e.g., with myocardin, SRF) alters specificity and gene targets.